rss
Br J Ophthalmol 2001;85:837-841 doi:10.1136/bjo.85.7.837
  • Original Article
    • Clinical science

CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART

  1. Hadi J Zambarakjia,
  2. Roger B Newsonb,
  3. Suzanne M Mitchella
  1. aDepartment of Ophthalmology, Chelsea and Westminster Hospital, London, UK, bDepartment of Epidemiology and Public Health, Division of Primary Care and Population Sciences, Imperial College School of Medicine, London, UK
  1. Miss Suzanne M Mitchell, Ophthalmology Department, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UKs.mitchell{at}doctors.org.uk
  • Accepted 22 November 2000

Abstract

AIM To assess the impact of highly active antiretroviral therapy (HAART) on the prevalence and progression of CMV retinitis (CMVR) among AIDS patients with baseline CD4 cell counts <100 cells × 106/l.

METHODS A longitudinal cohort study of 1292 patients. CD4 cell counts and HIV viral load measurements were obtained before commencing therapy, at 3 months, 1 year, 2 years, and at last follow up. The CMVR prevalence rate was measured for the subgroup with baseline CD4 cell counts <100 cells × 106/l. CMVR adverse event (AE) rates per 100 person days at risk were calculated for the subgroup with CMVR and baseline CD4 cell counts <100 cells × 106/l.

RESULTS 1292 patients were started on HAART. 8% of patients had CD4 counts <50 cells × 106/l and 40% had detectable HIV viral load at last follow up. The prevalence of CMVR for the subgroup with baseline CD4 <100 cells × 106/l was 10%. For those with baseline CD4 <100 cells × 106/l, the mean CMVR AE rate was greatest during the first 6 months of follow up after HAART commencement (p <0.003). The mean AE rate per 100 person days at risk was 0.36 (95% CI 0.167 to 0.551) before starting HAART, and 0.14 (95% CI 0.085 to 0.199) after starting HAART (p = 0.03).

CONCLUSIONS HAART significantly prolongs the disease-free intervals in patients with pre-existing disease but recurrences persist within the first 6 months of starting therapy. AE were absent beyond 18 months of follow up in all patients including those with persistently low CD4 counts and detectable HIV viral load indicating clinical immunorestoration. New methods for monitoring the response to therapy are needed to identify those at risk.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.